PEPGUIDE.net
Research-profile comparison

Semaglutide vs Tirzepatide: Research Comparison

Compare PepGuide's semaglutide and tirzepatide profiles side by side, including classification, evidence framing, and safety context.

Comparison page updated July 12, 2026
This page reuses reviewed summaries from the two underlying profiles. It is not a treatment comparison, dosing recommendation, or statement that the compounds have equivalent evidence.

Semaglutide

Approved pharmaceutical GLP-1 therapy

Semaglutide is a GLP-1 receptor agonist with approved uses in diabetes, obesity/weight management, and cardiovascular-risk contexts depending on product and label. It is not a research peptide in the same sense as BPC-157 or MOTS-c.

The evidence base is strong, but the formulation matters. Ozempic, Wegovy injection, Wegovy tablets, and Rybelsus have different labels, doses, administration rules, and outcome data. Compounded or counterfeit products are a separate risk category. Understand that slow titration is not optional convenience. It reduces GI side effects while the long half-life accumulates.

Full research profileLive prices

Tirzepatide

Approved pharmaceutical dual GIP/GLP-1 therapy

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with additional label expansion depending on current product status. It is a prescription drug, not a research peptide.

The evidence base is strong and comes from large SURPASS and SURMOUNT programs. Its long half-life means side effects, dose escalation, missed doses, and washout periods unfold more slowly than people may expect.

Full research profileLive prices